Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in December
November 23 2020 - 05:30PM
Business Wire
– Presentations to be webcast on
www.exelixis.com –
Exelixis, Inc. (Nasdaq: EXEL) today announced that members of
the company’s management team will participate in fireside chats at
the following virtual investor conferences in December:
- Piper Sandler 32nd Annual Virtual Healthcare Conference: Due to
the virtual nature of this year’s conference, presentation sessions
were pre-recorded and available on-demand. Exelixis’ fireside chat
session is now available to stream on the company’s website.
- Evercore ISI 3rd Annual HealthCONx: Exelixis is scheduled to
present at 3:05pm EST / 12:05pm PST on Tuesday, December 1,
2020.
To access the webcast links, log onto www.exelixis.com and
proceed to the News & Events / Event Calendar page under the
Investors & Media heading. Please connect to the company’s
website at least 15 minutes prior to the presentations to ensure
adequate time for any software download that may be required to
listen to the webcasts. Replays will also be available at the same
location for 14 days.
About Exelixis
Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially
successful, oncology-focused biotechnology company that strives to
accelerate the discovery, development and commercialization of new
medicines for difficult-to-treat cancers. Following early work in
model system genetics, we established a broad drug discovery and
development platform that has served as the foundation for our
continued efforts to bring new cancer therapies to patients in
need. Our discovery efforts have resulted in four commercially
available products, CABOMETYX® (cabozantinib), COMETRIQ®
(cabozantinib), COTELLIC® (cobimetinib) and MINNEBRO®
(esaxerenone), and we have entered into partnerships with leading
pharmaceutical companies to bring these important medicines to
patients worldwide. Supported by revenues from our marketed
products and collaborations, we are committed to prudently
reinvesting in our business to maximize the potential of our
pipeline. We are supplementing our existing therapeutic assets with
targeted business development activities and internal drug
discovery - all to deliver the next generation of Exelixis
medicines and help patients recover stronger and live longer.
Exelixis is a member of the Standard & Poor’s (S&P) MidCap
400 index, which measures the performance of profitable mid-sized
companies. In November 2020, the company was named to Fortune’s 100
Fastest-Growing Companies list for the first time, ranking 17th
overall and the third-highest biopharmaceutical company. For more
information about Exelixis, please visit www.exelixis.com, follow @ExelixisInc on Twitter
or like Exelixis, Inc. on Facebook.
Exelixis, the Exelixis logo, CABOMETYX,
COMETRIQ and COTELLIC are registered U.S. trademarks. MINNEBRO is a
registered Japanese trademark.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201123006282/en/
Investors Contact: Varant Shirvanian Sr. Investor
Relations Manager Exelixis, Inc. 650-837-7917
vshirvanian@exelixis.com
Media Contact: Hal Mackins For Exelixis, Inc.
415-994-0040 hal@torchcommunications.com
Exelixis (NASDAQ:EXEL)
Historical Stock Chart
From Feb 2024 to Mar 2024
Exelixis (NASDAQ:EXEL)
Historical Stock Chart
From Mar 2023 to Mar 2024